<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2026-41-3-81-89</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-3279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Клиническая характеристика пациентов с болезнью Фабри в российской популяции</article-title><trans-title-group xml:lang="en"><trans-title>Clinical characteristics of patients with Fabry disease in the Russian population</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5296-7622</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеев Алексей Сергеевич - канд. мед. наук, врач, клиника ревматологии, нефрологии и профпатологии им. Е.М. Тареева, Университетская клиническая больница № 3, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>119435, Москва, ул. Россолимо, 11/5</p></bio><bio xml:lang="en"><p>Alexey S. Moiseev - Cand. Sci. (Med.), Physician, E.M. Tareev Clinic of Rheumatology, Nephrology and Occupational Diseases, University Clinical Hospital No. 3, I.M. Sechenov First Moscow State Medical University (Sechenov University).</p><p>11/5, Rossolimo Street, Moscow, 119435</p></bio><email xlink:type="simple">moiseev7alexey@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3989-2590</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буланов</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Bulanov</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Буланов Николай Михайлович - канд. мед. наук, доцент кафедры внутренних, профессиональных болезней и ревматологии, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>119435, Москва, ул. Россолимо, 11/5</p></bio><bio xml:lang="en"><p>Nikolay M. Bulanov - Cand. Sci. (Med.), Associate Professor, Department of Internal, Occupational Diseases and Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).</p><p>11/5, Rossolimo Street, Moscow, 119435</p></bio><email xlink:type="simple">nmbulanov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-8251-6417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федулова</surname><given-names>Е. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedulova</surname><given-names>E. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федулова Евгения Романовна - клинический ординатор, кафедра внутренних, профессиональных болезней и ревматологии, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>119435, Москва, ул. Россолимо, 11/5</p></bio><bio xml:lang="en"><p>Evgeniya R. Fedulova - Clinical Resident, Department of Internal, Occupational Diseases and Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).</p><p>11/5, Rossolimo Street, Moscow, 119435</p></bio><email xlink:type="simple">erfedulova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1266-4926</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мершина</surname><given-names>Е. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Mershina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мершина Елена Александровна - канд. мед. наук, заведующий отделением рентгенодиагностики, компьютерной и магнитно-резонансной томографии, Университетская клиника Медицинского научно-образовательного института МГУ им. М.В. Ломоносова.</p><p>119234, Москва, пр-т Ломоносовский, 27, корп. 10</p></bio><bio xml:lang="en"><p>Elena A. Mershina - Cand. Sci. (Med.), Head of the Department of Diagnostic Radiology, Computed Tomography and Magnetic Resonance Imaging, University Clinic, Medical Research and Educational Institute, Lomonosov Moscow State University.</p><p>Corp. 10, 27, Lomonosov Avenue, Moscow, 119234</p></bio><email xlink:type="simple">elena_mershina@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7232-4640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеев Сергей Валентинович - д-р мед. наук, чл.-корр. РАН, заведующий кафедрой внутренних, профессиональных болезней и ревматологии и директор клиники им. Е.М. Тареева, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).</p><p>119435, Москва, ул. Россолимо, 11/5</p></bio><bio xml:lang="en"><p>Sergey V. Moiseev - Dr. Sci. (Med.), Corresponding Member of the Russian Academy of Sciences, Head of the Department of Internal, Occupational Diseases and Rheumatology, Director of the E.M. Tareev Clinic, I.M. Sechenov First Moscow State Medical University (Sechenov University).</p><p>11/5, Rossolimo Street, Moscow, 119435</p></bio><email xlink:type="simple">avt420034@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиника имени Е.М. Тареева, ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tareev Clinic of Internal Diseases, I. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский государственный университет имени М.В. Ломоносова (МГУ им. М.В. Ломоносова)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2026</year></pub-date><volume>41</volume><issue>3</issue><fpage>81</fpage><lpage>89</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Моисеев А.С., Буланов Н.М., Федулова Е.Р., Мершина Е.A., Моисеев С.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Моисеев А.С., Буланов Н.М., Федулова Е.Р., Мершина Е.A., Моисеев С.В.</copyright-holder><copyright-holder xml:lang="en">Moiseev A.S., Bulanov N.M., Fedulova E.R., Mershina E.A., Moiseev S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/3279">https://www.sibjcem.ru/jour/article/view/3279</self-uri><abstract><sec><title>Введение</title><p>Введение. Болезнь Фабри – Х-сцепленное лизосомное заболевание накопления с мультисистемным поражением, клинические проявления и тяжесть которого существенно различаются у мужчин и женщин. Разнообразие ранних симптомов и поражения органов-мишеней нередко приводит к поздней диагностике заболевания, в то время как своевременное установление диагноза имеет принципиальное значение для раннего начала специфической терапии.</p></sec><sec><title>Цель</title><p>Цель: изучить клинические проявления болезни Фабри у мужчин и женщин в российской популяции за период c 2015 по 2026 гг. для диагностики заболевания на ранних этапах.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведено ретроспективное когортное исследование со сравнительным анализом клинических проявлений болезни Фабри у взрослых мужчин и женщин. В когортное исследование, которое охватывало период с 2015 по 2026 гг., были включены 259 взрослых пациентов с болезнью Фабри, подтвержденной при молекулярно-генетическом исследовании (150 мужчин и 109 женщин; медиана возраста – 45,5 года). Для оценки поражения органов-мишеней определяли суточную альбуминурию, сывороточный уровень креатинина, проводили суточное мониторирование ЭКГ, эхокардиографию, магнитно-резонансную томографию (МРТ) сердца и головного мозга. Клинические проявления анализировали во всей выборке и отдельно у мужчин и женщин.</p></sec><sec><title>Результаты</title><p>Результаты. У большинства пациентов с детского или подросткового возраста наблюдались типичные ранние симптомы болезни Фабри, в том числе нейропатическая боль в кистях и стопах (67,6%), ангиокератомы (33,6%), вихревидная кератопатия (58,3%), снижение потоотделения (49,4%) и/или желудочно-кишечные нарушения (19,3%). Основными органами-мишенями при болезни Фабри являются почки, сердце и головной мозг, поражение которых было выявлено у 80,3; 61,0 и 48,3% пациентов соответственно. Несмотря на достаточно молодой возраст обследованных пациентов, у многих из них были зарегистрированы различные исходы заболевания, такие как диализзависимая хроническая почечная недостаточность (20,1%), инсульт (18,1%), в том числе повторный, и/или выраженная гипертрофия левого желудочка (ЛЖ) (21,6%), сопровождавшаяся аритмиями и/или хронической сердечной недостаточностью. Смертность во время периода наблюдения составила 12,7%. У мужчин заболевание характеризовалось более тяжелым течением и более ранним развитием неблагоприятных исходов.</p></sec><sec><title>Заключение</title><p>Заключение. Предполагать болезнь Фабри у взрослых пациентов следует при наличии нефропатии или гипертрофии миокарда ЛЖ неясного происхождения и/или инсульта, развившегося в молодом возрасте, а также типичных ранних проявлений заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Fabry disease is an X-linked lysosomal storage disorder with multisystem involvement, the clinical manifestations and severity of which differ significantly between males and females. The diversity of early symptoms and target organ damage often leads to delayed diagnosis, while timely diagnosis is essential for early initiation of specific therapy.</p></sec><sec><title>Aim</title><p>Aim: To study the clinical features of Fabry disease in males and females in the Russian population over the period from 2015 to 2026 for early diagnosis of the disease.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. A retrospective cohort study with a comparative analysis of clinical manifestations of Fabry disease in adult males and females was conducted. The cohort study, covering the period from 2015 to 2026, included 259 adult patients with Fabry disease confirmed by molecular genetic testing (150 males and 109 females; median age 45.5 years). To assess target organ damage, daily albuminuria, serum creatinine levels, 24-hour Holter ECG monitoring, echocardiography, cardiac and brain magnetic resonance imaging (MRI) were performed. Clinical manifestations were assessed in the overall cohort and separately in males and females.</p></sec><sec><title>Results</title><p>Results. The majority of patients had typical early manifestations of Fabry disease from childhood or adolescence, including neuropathic pain in the hands and feet (67.6%), angiokeratomas (33.6%), cornea verticillata (58.3%), hypohidrosis (49.4%), and/or gastrointestinal symptoms (19.3%). The target-organ involvement, that is, kidney, heart, and brain disease, was detected in 80.3%, 61.0%, and 48.3% of patients, respectively. Despite the relatively young age of the examined patients, many presented various disease outcomes, such as dailysis-dependent chronic renal failure (20.1%), stroke (18.1%), including recurrent stroke, and/or severe left ventricular hypertrophy (LVH) (21.6%) accompanied by arrhythmias and/or chronic heart failure. Mortality during follow-up was 12.7%. Male patients had a more severe clinical course of Fabry disease and developed adverse outcomes at younger age.</p></sec><sec><title>Conclusion</title><p>Conclusion. Fabry disease should be suspected in adults patients with nephropathy or left ventricular hypertrophy of unknown origin and/or stroke at a young age, particularly when these findings are accompanied by typical early manifestations of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Фабри</kwd><kwd>LysoGL3</kwd><kwd>α-галактозидаза А</kwd><kwd>нефропатия</kwd><kwd>гипертрофия левого желудочка</kwd><kwd>инсульт</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Fabry disease</kwd><kwd>LysoGL3</kwd><kwd>α-galactosidase A</kwd><kwd>nephropathy</kwd><kwd>left ventricular hypertrophy</kwd><kwd>stroke</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010;5:30. DOI: 10.1186/1750-1172-5-30</mixed-citation><mixed-citation xml:lang="en">Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010;5:30. DOI: 10.1186/1750-1172-5-30</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wilcox W.R., Oliveira J.P., Hopkin R.J., et al.; Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 2008;93(2):112–128. DOI: 10.1016/j.ymgme.2007.09.013</mixed-citation><mixed-citation xml:lang="en">Wilcox W.R., Oliveira J.P., Hopkin R.J., et al.; Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 2008;93(2):112–128. DOI: 10.1016/j.ymgme.2007.09.013</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Moiseev S., Fomin V., Savostyanov K., et al. The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019;141(4):249–255. DOI: 10.1159/000495886</mixed-citation><mixed-citation xml:lang="en">Moiseev S., Fomin V., Savostyanov K., et al. The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019;141(4):249–255. DOI: 10.1159/000495886</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Moiseev S., Tao E., Moiseev A., et al. The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients. Genes (Basel). 2022;13(9):1619. DOI: 10.3390/genes13091619</mixed-citation><mixed-citation xml:lang="en">Moiseev S., Tao E., Moiseev A., et al. The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients. Genes (Basel). 2022;13(9):1619. DOI: 10.3390/genes13091619</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев С.В., Исмаилова Д.С., Моисеев А.С. и др. Вихревидная кератопатия (cornea verticillata) при болезни Фабри. Терапевт. арх. 2018;90(12):17–22. DOI: 10.26442/00403660.2018.12.000003 EDN: YROFTN</mixed-citation><mixed-citation xml:lang="en">Moiseev S.V., Ismailova D.S., Moiseev A.S., et al. Cornea verticillata in Fabry disease. Terapevticheskii arkhiv = Therapeutic Archive. 2018;90(12):17–22. (In Russian). DOI: 10.26442/00403660.2018.12.000003 EDN: YROFTN</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Moiseev S., Karovaikina E., Novikov P.I., et al. What rheumatologist should know about Fabry disease. Ann. Rheum. Dis. 2020;79(6):e71. DOI: 10.1136/annrheumdis-2019-215476</mixed-citation><mixed-citation xml:lang="en">Moiseev S., Karovaikina E., Novikov P.I., et al. What rheumatologist should know about Fabry disease. Ann. Rheum. Dis. 2020;79(6):e71. DOI: 10.1136/annrheumdis-2019-215476</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Reisin R., Perrin A., García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. Int. J. Clin. Pract. 2017;71(1):e12914. DOI: 10.1111/ijcp.12914</mixed-citation><mixed-citation xml:lang="en">Reisin R., Perrin A., García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. Int. J. Clin. Pract. 2017;71(1):e12914. DOI: 10.1111/ijcp.12914</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Smid B.E., van der Tol L., Cecchi F., et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int. J. Cardiol. 2014;177(2):400–408. DOI: 10.1016/j.ijcard.2014.09.001</mixed-citation><mixed-citation xml:lang="en">Smid B.E., van der Tol L., Cecchi F., et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int. J. Cardiol. 2014;177(2):400–408. DOI: 10.1016/j.ijcard.2014.09.001</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nowak A., Beuschlein F., Sivasubramaniam V., et al. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J. Med. Genet. 2022;59(3):287–293. DOI: 10.1136/jmedgenet-2020-107338</mixed-citation><mixed-citation xml:lang="en">Nowak A., Beuschlein F., Sivasubramaniam V., et al. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J. Med. Genet. 2022;59(3):287–293. DOI: 10.1136/jmedgenet-2020-107338</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Baydakova G.V., Ilyushkina A.A., Moiseev S., et al. α-Galactosidase A/ lysoGb3 ratio as a potential marker for Fabry disease in females. Clin. Chim. Acta. 2020;501:27–32. DOI: 10.1016/j.cca.2019.10.031</mixed-citation><mixed-citation xml:lang="en">Baydakova G.V., Ilyushkina A.A., Moiseev S., et al. α-Galactosidase A/ lysoGb3 ratio as a potential marker for Fabry disease in females. Clin. Chim. Acta. 2020;501:27–32. DOI: 10.1016/j.cca.2019.10.031</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Каровайкина Е.А., Моисеев С.В., Буланов Н.М. и др. Распространенность и основные проявления поражения почек у пациентов с болезнью Фабри. Клин. фармакол. тер. 2018;27(4):46–52. EDN: VACFLK</mixed-citation><mixed-citation xml:lang="en">Karovaikina E.A., Moiseev S.V., Bulanov N.M., et al. Prevalence and clinical manifestations of nephropathy in patients with Fabry disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2018;27(4):46–52. (In Russ.). EDN: VACFLK</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz A., Oliveira J.P., Waldek S., et al. Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant. 2008;23(5):1600–1607. DOI: 10.1093/ndt/gfm848</mixed-citation><mixed-citation xml:lang="en">Ortiz A., Oliveira J.P., Waldek S., et al. Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant. 2008;23(5):1600–1607. DOI: 10.1093/ndt/gfm848</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев А.С., Буланов Н.М., Федулова Е.Р. и др. Фибрилляция предсердий при болезни Фабри. Клин. фармакол. тер. 2025;34(4):49–54. DOI: 10.32756/0869-5490-2025-49-54 EDN: CGHSWA</mixed-citation><mixed-citation xml:lang="en">Moiseev A.S., Bulanov N.M., Fedulova E.R., et al. Atrial fibrillation in Fabry disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2025;34(4):49–54. (In Russ.). DOI: 10.32756/0869-5490-2025-49-54 EDN: CGHSWA</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Linhart A., Kampmann C., Zamorano J.L., et al.; European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 2007;28(10):1228–1235. DOI: 10.1093/eurheartj/ehm153</mixed-citation><mixed-citation xml:lang="en">Linhart A., Kampmann C., Zamorano J.L., et al.; European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 2007;28(10):1228–1235. DOI: 10.1093/eurheartj/ehm153</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев А.С., Мершина Е.А., Сафарова А.Ф. и др. Поражение сердца при болезни Фабри: особенности течения и диагностическое значение магнитно-резонансной томографии и speckle-tracking эхокардиографии. Клин. фармакол. тер. 2022;31(3):22–29. DOI: 10.32756/0869-5490-2022-3-22-29 EDN: JEGXHB</mixed-citation><mixed-citation xml:lang="en">Moiseev A.S., Mershina E.A., Safarova A.F., et al. Heart involvement in Fabry disease: clinical features, cardiac MRI and speckle-tracking echocardiography. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2022;31(3):22–29. (In Russ.) DOI: 10.32756/0869-5490-2022-3-22-29 EDN: JEGXHB</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tao E., Moiseev A., Mershina E., et al. Predictive Value of Cardiac MRI in Patients with Fabry Disease. Radiology. 2020;296(2):E123. DOI: 10.1148/radiol.2020200909</mixed-citation><mixed-citation xml:lang="en">Tao E., Moiseev A., Mershina E., et al. Predictive Value of Cardiac MRI in Patients with Fabry Disease. Radiology. 2020;296(2):E123. DOI: 10.1148/radiol.2020200909</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Körver S., Vergouwe M., Hollak C.E.M., et al. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol. Genet. Metab. 2018;125(3):205–216. DOI: 10.1016/j.ymgme.2018.08.014</mixed-citation><mixed-citation xml:lang="en">Körver S., Vergouwe M., Hollak C.E.M., et al. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol. Genet. Metab. 2018;125(3):205–216. DOI: 10.1016/j.ymgme.2018.08.014</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Тао Е.А., Моисеев А.С., Буланов Н.М. и др. Клинические фенотипы болезни Фабри у 219 взрослых пациентов. Клин. фармакол. тер. 2024;33(2):56–62. DOI: 10.32756/0869-5490-2024-2-56-62 EDN: AHCMEU</mixed-citation><mixed-citation xml:lang="en">Tao E.A., Moiseev A.S., Bulanov N.M. et al. Clinical phenotypes of Fabry disease in 219 adult patients. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2024;33(2):56–62. (In Russ.) DOI: 10.32756/0869-5490-2024-2-56-62 EDN: AHCMEU</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Viggiano E., Politano L. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Int. J. Mol. Sci. 2021;22(14):7663. DOI: 10.3390/ijms22147663</mixed-citation><mixed-citation xml:lang="en">Viggiano E., Politano L. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Int. J. Mol. Sci. 2021;22(14):7663. DOI: 10.3390/ijms22147663</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев А.С., Буланов Н.М., Тао Е.А. и др. Эффективность и безопасность длительной ферментозаместительной терапии агалсидазой альфа и агалсидазой бета у взрослых пациентов с болезнью Фабри. Клин. фармакол. тер. 2022;31(4):28–34. DOI: 10.32756/0869-5490-2022-4-28-34 EDN: UVDQWZ</mixed-citation><mixed-citation xml:lang="en">Moiseev A.S., Bulanov N.M., Tao E.A., et al. Efficacy and safety of long-term enzyme replacement therapy with agalsidase alfa or agalsidase beta in adult patients with Fabry disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2022;31(4):28–34. (In Russ.). DOI: 10.32756/0869-5490-2022-4-28-34 EDN: UVDQWZ</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев С.В., Тао Е.А., Моисеев А.С., Буланов Н.М. Пэгунигалсидаза альфа – новый пегилированный рекомбинантный препарат альфа-галактозидазы для ферментозаместительной терапии болезни Фабри. Клин. фармакол. тер. 2024;33(3):57–62. DOI: 10.32756/0869-5490-2024-3-57-62 EDN: KNPEYO</mixed-citation><mixed-citation xml:lang="en">Moiseev S.V., Tao E.A., Moiseev A.S., Bulanov N.M. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme replacement therapy for Fabry disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2024;33(3):57–62. (In Russ.). DOI: 10.32756/0869-5490-2024-3-57-62 EDN: KNPEYO</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes D., Linhart A., Gurevich A., et al.; FOS Study Group. Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis. Drug Des. Devel. Ther. 2021;15:3561–3572. DOI: 10.2147/DDDT.S313789</mixed-citation><mixed-citation xml:lang="en">Hughes D., Linhart A., Gurevich A., et al.; FOS Study Group. Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis. Drug Des. Devel. Ther. 2021;15:3561–3572. DOI: 10.2147/DDDT.S313789</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
